Stay updated with breaking news from Early drug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi that endangers almost 70 million people worldwide. The only two drugs that are currently approved for its treatment, benznidazole and nifurtimox, have controversial efficacy in adults and restricting safety issues, leaving thousands of patients without a suitable treatment. The neglect of Chagas disease is further illustrated by the lack of a robust and diverse drug discovery and development portfolio of new chemical entities, and it is of paramount importance to build a strong research and development network for antichagasic drugs. Focusing on drug discovery programs led by scientists based in Latin America, the main endemic region for this disease, we discuss herein what has been published in the last decade in terms of identification of new antiparasitic drugs to treat Chagas disease, shining a spotlight on the origin, chemical diversity, level of characterization of hits, and strategi ....
Combination Accelerates Outcomes in Early Drug Discovery X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule ....
SLAS Discovery's September special collection "Applications of biophysics in early drug discovery" now available miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Considerations for Immunology and Immunotoxicology Endpoints in Early Drug Development, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss immunology and immunotoxicology endpoints and how to assess the immune response in early drug development. The presentation will explore the range of immunology endpoint assessments available and their respective uses for developing safe and effective therapeutics. This talk will outline when to consider different I&I assay services and the regulatory and scientific considerations for these that will influence the appropriate biological interpretation of the immune response. TORONTO, Ontario (PRWEB) April 06, 2021 There are many considerations for Immunology and Immunotoxicology (I&I) assessments that are needed during the early phase of drug development. This talk will outline when to consider differe ....